Alerts
Kidney Cancer Has a New Post-Immunotherapy Standard. Survival Is Not Settled.
FDA has approved belzutifan plus lenvatinib after PD-1 or PD-L1 therapy in advanced clear-cell renal cell carcinoma. The combination improved progression-free survival and response against cabozantinib. Overall survival did not cross the statistical line.
In Australia, Cancer Medicine Delays Cost More Than Time
Wellness Powder Sent 32 People to Hospital
Fungal Disease Was Left Out of the AMR Fight
BRCA Care Cannot Start at Diagnosis
Duchenne’s Accelerated Approval Faces Its Test
The Screwworm Border Did Not Hold. Now Mexico and the U.S. Are Betting on Flies.
Europe Opens Another Lung Cancer Door to China-Origin Immunotherapy
In Australia, Cancer Medicine Delays Cost More Than Time
Cancer Progress Still Depends on Your Postcode
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.